SecBot SecBot
PRESS-RELEASE ·Filed Aug 14, 2026

FATE

Fate Therapeutics, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor enrollment updates and interim data readouts from RECLAIM-LN. The RMAT designation and FDA CMC pilot program support accelerated pathway, but no efficacy data expected for 12-18 months. Stock movement likely driven by enrollment pace and any early safety signals.

DirectionBullish
Confidencemedium
Horizonmonths

FT819

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
Next catalyst
None dated

What to watchThe next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.57
T+0 close · Aug 14, 2026 · via day close
Latest settled
−24.51%
T+60 · $1.94
Vs SPY
−21.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $2.57entry
  2. T+1 · 3mo ago +1.95%α +2.42% · $2.62
  3. T+5 · 3mo ago −9.34%α −7.97% · $2.33
  4. T+20 · 2mo ago −8.95%α −6.96% · $2.34
  5. T+60 · 8d ago −24.51%α −21.47% · $1.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for lupus nephritis. The trial targets ~53 patients with enrollment expected to complete by 1H2028, supported by RMAT designation and FDA CMC pilot program. This is a positive clinical milestone but no efficacy data is expected for 12-18 months.

Key Facts

  • First patient dosed in Phase 2 RECLAIM-LN trial (FT819) for refractory lupus nephritis
  • Trial expected to enroll ~53 patients; enrollment completion anticipated by 1H2028
  • Primary endpoint: complete renal response at Week 26
  • FT819 has RMAT designation and is in FDA CMC Development and Readiness Pilot program
  • Patients receive single 900M-cell dose of off-the-shelf FT819 with bendamustine conditioning

Financial Impact

Clinical milestone with no immediate revenue impact; trial enrollment expected to complete by 1H2028. Cash runway into 2028 per prior Q2 filing.

clinical trial progresspipeline value

Risk Factors

  • Trial enrollment delays or slower-than-expected site activation
  • Negative efficacy or safety data from Phase 2
  • Dilution risk given cash burn and no revenue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345223

Track record

21 reports on FATE

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026